Research progress of Scutellaria barbata against colorectal cancer and its metastasis mechanism

doi:10.12092/j.issn.1009-2501.2019.03.016

Abstract

Abstract:

Colorectal cancer is one of the common malignant tumors in the digestive tract. Because it is difficult to eradicate and it is highly prone to metastasize, it brings difficulty in treatment. In recent years, studies have shown that traditional Chinese medicine Scutellaria barbata can be used for molecular targeted therapy of colorectal cancer and its metastasis through a variety of approaches, mainly including four aspects: signal transduction pathways, related tumor suppressor genes, telomerase activity, and body immunity. Here we review the main approaches in hope of providing referential idea for its clinical application.

Key words: Scutellaria barbata, colorectal cancer, metastasis, molecular mechanism

CLC Number:

QIAO Dawei, LI Yufang, XIAO Yun, JIANG Lishuang, BO Ping. Research progress of Scutellaria barbata against colorectal cancer and its metastasis mechanism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 332-336.

References

［1］Gong C, Long ZP, Yu YM, et al. Dietary factors and polymorphisms in vitamin D metabolism genes: the risk and prognosis of colorectal cancer in northeast China［J］.Sci Rep,2017,7:8827.
［2］Chen W, Zheng R, Baade PD,et al. Cancer statistics in China［J］.CA Cancer J Clin,2016,66(2):115-132.
［3］国家药典委员会.中华人民共和国药典一部［M］.北京:中国医药科技出版社,2015 :70.
［4］Jiang Q, Li Q, Chen H, et al. Scutellaria barbata D. Don inhibits growth and induces apoptosis by suppressing IL-6-inducible STAT3 pathway activation in human colorectal cancer cells［J］.Exp Ther Med,2015,10(4):1602-1608.
［5］Wei LH, Lin JM. Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway［J］.Chin J Integr Med,2017,23(11):858-863.
［6］Wei L, Lin J, Wu G, et al. Scutellaria barbata D. Don induces G1/S arrest via modulation of p53 and Akt pathways in human colon carcinoma cells［J］.Oncol Rep,2013,29(4):1623-1628.
［7］Jin Y, Chen W, Yang H,et al. Scutellaria barbata D. Don inhibits migration and invasion of colorectal cancer cells via suppression of PI3K/AKT and TGF-β/Smad signaling pathways［J］.Exp Ther Med,2017,14(6):5527-5534.
［8］Sun P,Sun D,Wang X. Effects of Scutellaria barbata polysaccharide on the proliferation, apoptosis and EMT of human colon cancer HT29 Cells［J］.Carbohydr Polym,2017,167:90-96.
［9］Wei L,Lin J,Xu W,et al.Scutellaria barbata D. Don inhibits tumor angiogenesis via suppression of Hedgehog pathway in a mouse model of colorectal cancer［J］.Int J Mol Sci,2012,13(8):9419-9430.
［10］Lin J,Feng J,Yang H,et al.Scutellaria barbata D.Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway［J］.Oncol Rep,2017,38(4):2293-2300.
［11］Ferracin M,Lupini L,Mangolini A, et al. Circulating non-coding RNA as biomarkers in colorectal cancer［J］.Adv Exp Med Biol,2016,937:171-181.
［12］Hur K,Toiyama Y,Schetter AJ, et al.Identification of a metastasis-specific MicroRNA signature in human colorectal cancer［J］.J Natl Cancer Inst,2015,107(3).
［13］Zhang L,Fang Y,Feng JY,et al.Chloroform fraction of Scutellaria barbata D. Don inhibits the growth of colorectal cancer cells by activating miR-34a［J］.Oncol Rep,2017,37(6):3695-3701.
［14］石梦莹.基于mciroRNA-200a的半枝莲抗肠道肿瘤细胞SW480上皮间质转化的研究［D］.成都中医药大学,2016.
［15］Yang N,Zhao Y,Wang Z,et al.Scutellarin suppresses growth and causes apoptosis of human colorectal cancer cells by regulating the p53 pathway［J］.Mol Med Rep,2017,15(2):929-935.
［16］Popli DB,Sircar K,Chowdhry A.Telomerase: An exploration toward the end of cancer［J］.Indian J Dent Res,2017,28(5):574-584.
［17］Lipinska N,Romaniuk A,Paszel-Jaworska A,et al.Telomerase and drug resistance in cancer［J］.Cell Mol Life Sci,2017,74(22):4121-4132.
［18］C Pinolfelis,T Fernándezmarcelo,J Vinassalas,et al.Telomeres and telomerase in the clinical management of colorectal cancer［J］.Clin Transl Oncol,2017,19(4):399-408.
［19］Nikolouzakis TK,Vassilopoulou L,Fragkiadaki P,et al.Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review)［J］.Oncol Rep,2018, 39(6):2455-2472.
［20］Engelhardt M,Drullinsky P,Guillem J, et al. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer［J］.Clin Cancer Res,1997,3(11):1931-1941.
［21］Engelhardt M,Albanell J,Drullinsky P, et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma.Clin［J］.Cancer Res,1997,3(10):1849-1857.
［22］Norppa H, Falck GC.What do human micronuclei contain ［J］? Mutagenesis,2003,18(3):221-233.
［23］Farhadi S, Mohamadi M, Mohamadi M. Repair index in examination of nuclear changes in the buccal mucosa of smokers: A useful method for screening of oral Cancer［J］.Asian Pac J Cancer Prev,2017,18(11):3087-3090.
［24］Ionescu EM,Nicolaie T,Ionescu MA, et al. Predictive cytogenetic biomarkers for colorectal neoplasia in medium risk patients［J］.J Med Life,2015,8(3):398-403.
［25］陈泽雄,陈雯,张诗军.抗癌方抑制人结肠癌细胞增殖及端粒酶活性［J］.中国中西医结合杂志,2000(s1):67-68.
［26］李伟,梁慧,谢胜军.肠复方对晚期大肠癌患者外周血CK20 mRNA、端粒酶表达的影响［J］.中医杂志，2017,58(11):941-945.
［27］赵田禾,张莹莹,吴洋洋,等.汉黄芩素及其衍生物的抗肿瘤作用及其分子机制的研究进展［J］.中国新药杂志,2016, (25)7:760-766.
［28］Son YO,Kook SH,Lee JC,et al.Glycoproteins and polysaccharides are the main class of active constituents required for lymphocyte stimulation and antigen-specific immune response induction by traditional medicinal herbal plants［J］.J Med Food,2017,20(10): 1011-1021.
［29］曹军.自拟益气解毒汤对大肠癌(气血亏虚证)患者肿瘤标志物及免疫功能的影响［J］.四川中医,2017,35(3):82-84.

[1]	SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun. Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
[2]	WEI Zhenzhen, SUI Hua, JIANG Yulang, SUN Mingyu, YAN Huaru, WANG Ziyuan. Research on the molecular mechanism of Zuo Jin Wan combined with cetuximab inducing ferroptosis in KRAS mutant colorectal cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 130-137.
[3]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[4]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[5]	ZHANG Wei, WANG Yingbin, CAO Lu, LIU Yan, ZHANG Li, LIU Jieting. Research progress of autophagy in intestinal ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1061-1066.
[6]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[7]	ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587.
[8]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
[9]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[10]	LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian. OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407.
[11]	YI Hong, GU Bing, CHEN Yunian, LI Huanan. Neutrophil extracellular traps and its role in gouty diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1167-1173.
[12]	SONG Dandan, CHEN Xueyuan, CHEN Ruiqi, LI Hanqiao, WU Tian. Research status of long non-coding RNA MALAT1 in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 49-57.
[13]	ZHANG Dezhi, LIU Meng, ZHU Shaogong, LIU Guiju, JI Jie. Efficacy and safety of XELOX therapy in comparison with capecitabine monotherapy in adjuvant chemotherapy for elderly patients with colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 926-936.
[14]	WANG Ziyuan, SUN Mingyu. Advances in research on long non-coding RNA in drug resistance of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
[15]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.